Biodesix to Participate in the TD Cowen 44th Annual Health Care Conference
26 Februar 2024 - 12:00PM
Business Wire
Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions
company with a focus in lung disease, announced today that Scott
Hutton, Chief Executive Officer of Biodesix, will present and host
in-person 1x1 investor meetings at the TD Cowen 44th Annual Health
Care Conference, which will be held from March 4-6, 2024.
TD Cowen 44th Annual Health Care Conference Presentation
Date: Monday, March 4, 2024 Presentation Time: 10:30 AM ET
Location: Marriot Copley Place, Boston, MA
The presentation will be webcast live and available for replay
under “News & Events” in the Investors section of Biodesix's
website at Biodesix.com.
About Biodesix
Biodesix is a leading diagnostic solutions company with a focus
in lung disease. The company develops diagnostic tests addressing
important clinical questions by combining multi-omics through the
power of artificial intelligence. Biodesix offers five
Medicare-covered tests for patients with lung diseases. The blood
based Nodify Lung® nodule risk assessment testing strategy,
consisting of the Nodify XL2® and the Nodify CDT® tests, evaluates
the risk of malignancy in pulmonary nodules, enabling physicians to
better triage patients to the most appropriate course of action.
The blood based IQLung™ strategy for lung cancer patients
integrates the GeneStrat® targeted ddPCR™ test, the GeneStrat NGS®
test and the VeriStrat® test to support treatment decisions across
all stages of lung cancer with results in an average of two to
three business days, expediting the time to treatment. Biodesix
also leverages the proprietary and advanced Diagnostic Cortex® AI
(Artificial Intelligence) platform, to collaborate with many of the
world’s leading biotechnology and pharmaceutical companies to solve
complex diagnostic challenges in lung disease. For more information
about Biodesix, visit biodesix.com.
Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements that
involve substantial risks and uncertainties for purposes of the
safe harbor provided by the Private Securities Litigation Reform
Act of 1995. All statements contained in this press release other
than statements of historical fact, are forward-looking statements.
The words “believe,” “may,” “will,” “estimate,” “continue,”
“anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,”
“opportunity,” “goals,” or “should,” and similar expressions are
intended to identify forward-looking statements. Such statements
are based on management’s current expectations and involve risks
and uncertainties. Actual results and performance could differ
materially from those projected in the forward-looking statements
as a result of many factors. Biodesix has based these
forward-looking statements largely on its current expectations and
projections about future events and trends. These forward-looking
statements are subject to a number of risks, uncertainties, and
assumptions. Forward-looking statements may include information
concerning the impact of the COVID-19 pandemic on Biodesix and its
operations, its possible or assumed future results of operations,
including descriptions of its revenues, profitability, outlook, and
overall business strategy. Forward-looking statements are
inherently subject to risks and uncertainties, some of which cannot
be predicted or quantified. The Company's ability to continue as a
going concern could cause actual results to differ materially from
those contemplated in this press release and additionally, other
factors that could cause actual results to differ materially from
those contemplated in this press release can be found in the Risk
Factors section of Biodesix’s most recent annual report on Form
10-K, filed March 6, 2023 or subsequent quarterly reports on Form
10-Q during 2023, if applicable. Biodesix undertakes no obligation
to revise or publicly release the results of any revision to such
forward-looking statements, except as required by law. Given these
risks and uncertainties, readers are cautioned not to place undue
reliance on such forward-looking statements. All forward-looking
statements are qualified in their entirety by this cautionary
statement.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240226485773/en/
Media: Natalie St. Denis Director, Corporate
Communications Natalie.StDenis@biodesix.com 1-720-925-9285
Investors: Chris Brinzey ICR Westwicke
chris.brinzey@westwicke.com 1-339-970-2843
Biodesix (NASDAQ:BDSX)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Biodesix (NASDAQ:BDSX)
Historical Stock Chart
Von Mai 2023 bis Mai 2024